Tyrosine
drugOn this page
Also known as FEMA NO. 3736L-tyrosineLevodopa impurityl-tyrosine-Levodopa related compound l-tyrosineNSC-82624TirosinaL-Tyr(S)-TyrosineSID29215265SID144205147SID170466853DL-TYROSINE
Summary
Tyrosine (CHEMBL925) is an approved small-molecule EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; indicated across 3 conditions including type 2 diabetes mellitus and nemaline myopathy.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- Indications: 3 conditions
- Clinical trials: 17
- Chemistry: 181.19 Da · C9H11NO3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL925 |
| Name | Tyrosine |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 6057 |
| ChEBI | CHEBI:17895 |
| Molecular formula | C9H11NO3 |
| Molecular weight | 181.19 |
| InChIKey | OUYCCCASQSFEME-QMMMGPOBSA-N |
SMILES: C1=CC(=CC=C1C[C@@H](C(=O)O)N)O
IUPAC name: (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
ChEBI definition: An optically active form of tyrosine having L-configuration.
Pharmacological roles (ChEBI): EC 1.3.1.43 (arogenate dehydrogenase) inhibitor, nutraceutical, micronutrient.
Other ChEBI roles (chemical / environmental): fundamental metabolite.
Also known as: FEMA NO. 3736, L-tyrosine, Levodopa impurity, l-tyrosine-, Levodopa related compound l-tyrosine, NSC-82624, Tirosina, Tyrosine, L-Tyr, (S)-Tyrosine, L-Tyrosine, TYROSINE
Patent coverage: 232,091 distinct patent families (703,519 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Large neutral amino acids transporter small subunit 1.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| type 2 diabetes mellitus | 4 | MONDO:0005148 | MONDO:0005148 |
| nemaline myopathy | 2 | MONDO:0018958 | MONDO:0018958 |
| obesity disorder | 1 | MONDO:0011122 | EFO:0001073 |
Clinical trials
Total trials: 17.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 12 |
| PHASE2 | 2 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00000322 | PHASE2 | COMPLETED | Tyrosine for Methamphetamine Dependence - 1 |
| NCT01676103 | PHASE1/PHASE2 | COMPLETED | The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson’s Disease |
| NCT02035501 | PHASE2 | UNKNOWN | Treatment of TNNT1-Myopathy With L-Tyrosine. |
| NCT00302289 | PHASE1 | COMPLETED | B181: Stimulation of Thermogenesis by Bio-Active Food Ingredients |
| NCT02259049 | EARLY_PHASE1 | COMPLETED | The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson’s Disease |
| NCT05782829 | Not specified | RECRUITING | Perioperative Stress Management in Outpatient Surgery With L-tyrosine Supplementation (SPOT) |
| NCT07530185 | Not specified | NOT_YET_RECRUITING | Effects of L-Tyrosine and Caffeine on Performance in Elite Boxers |
| NCT07532330 | Not specified | ACTIVE_NOT_RECRUITING | Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo |
| NCT00865514 | Not specified | TERMINATED | Pharmacotoxicology of Trichloroethylene Metabolites |
| NCT01219049 | Not specified | TERMINATED | L-Tyrosine Supplementation in Patients With Fibromyalgia |
| NCT01494766 | Not specified | COMPLETED | Efficacy of Tyrosine in Restless Legs Syndrome |
| NCT02223299 | Not specified | WITHDRAWN | Pilot Study: Combining Nutritional Supplements With Standard Antidepressant to Treat Depression. |
| NCT03068884 | Not specified | COMPLETED | Dopamine Dorsolateral Prefrontal Cortex Behavioural Flexibility |
| NCT03673995 | Not specified | COMPLETED | Myoinositol Plus L-tyrosine, Selenium and Chromium in PCOS |
| NCT04204174 | Not specified | UNKNOWN | Identification of P-cresyl Sulfate Producer Phenotype by Oral Tyrosine Challenge Test: Interactions Among Diet, Gut Microbiota, and Host Genome |
| NCT04518254 | Not specified | COMPLETED | Contribution of L-Tyrosine to Human Decision Making in Stressful Situations |
| NCT04549194 | Not specified | COMPLETED | Contribution of L-Tyrosine to Recovery From Operational Strain on Return From External Operation |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: type 2 diabetes mellitus